Recent clinical observation in treatment of chemotherapy-failed advanced lung adenocarcinoma cases with apatinib
10.3760/cma.j.issn.1008-6315.2016.10.014
- VernacularTitle:阿帕替尼治疗化疗失败的晚期肺腺癌近期效果观察
- Author:
Lei LI
;
Weidong ZHANG
;
Xuhui WANG
;
Xiaoping LI
- Publication Type:Journal Article
- Keywords:
Apatinib;
Lung adenocarcinoma;
Efficacy;
Adverse reactions
- From:
Clinical Medicine of China
2016;32(10):917-920
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the treatment of chemotherapy?failed advanced lung adenocarcinoma cases and the adverse reactions with apatinib. Method Twenty?two patients received treatment of apatinib at a dose of 425 mg/day for two weeks,then at a dose of 675 mg/day for two weeks if could be tolerated. The efficacy was evaluated by the imaging,CEA and NSE. Results The clinical evaluation of patients were complete remis?sion( CR) 0 case,partial remission( PR) 5 cases,steady( SD) 13 cases,progress( PD) 3 cases,1 case termina?ted the treatment due to adverse reactions,and the objective response rate was 23. 8%(5/21),disease control rate was 85. 7%(18/21). After 4 weeks treatment,CEA and NSE were significantly reduced than the previous ((97. 45±79. 05) mg/L vs. (47. 05±31. 89) mg/L,(20. 27±6. 88) mg/L vs. (11. 09±8. 92) mg/L;t=2. 45, 3. 56;P<0. 05) . The impacts on prognosis of different metastatic sites were no statistical significant difference( P>0. 05) . The main side effects were hypertension and proteinuria( 72. 7%,59. 0%) . Conclusion The treatment of chemotherapy?failed advanced lung adenocarcinoma with apatinib has better exact effect,and toxicity could be controlled,so it was worthy of clinical treatment and evaluation of long?term efficacy.
